Lifelong therapy with mineralocorticoid receptor antagonists (MRAs) or surgical
adrenalectomy are the recommended treatments for primary aldosteronism (PA). Whether …

Background In patients with primary aldosteronism (PA), long-term cardiovascular and
mortality outcomes after adrenalectomy vs mineralocorticoid receptor antagonist (MRA) …

There exists a great knowledge gap in terms of long-term effects of various surgical and
pharmacological treatments on outcomes among primary aldosteronism (PA) patients. Using …

Background Mineralocorticoid receptor (MR) antagonists are the recommended medical
therapy for primary aldosteronism. Whether this recommendation effectively reduces …

Primary aldosteronism (PA) is an endocrinopathy characterized by dysregulated
aldosterone production that occurs despite suppression of renin and angiotensin II, and that …

Objective Primary aldosteronism (PA) has deleterious effects on kidney function
independent of blood pressure levels. Up to now, data on effectiveness of different PA …

Objectives: In experimental animal models, exogenous aldosterone excess has been linked
to the progression of renal disease. However, the evidence of an increased risk of renal …

We are witnessing a revolution in our understanding of primary aldosteronism (PA). In the
past 2 decades, we have learned that PA is a highly prevalent syndrome that is largely …

Context: In primary aldosteronism (PA), glomerular hyperfiltration due to excessive
aldosterone is considered to underestimate actual renal damage. Objective: Our objectives …

Primary aldosteronism (PA) is one of the common forms of curable hypertension. Recent
views have suggested that PA is far from being relatively benign, as it was previously …